Cargando…
Role of rituximab in first-line treatment of chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous illness that primarily afflicts the elderly. For many decades, the initial therapy for most patients requiring treatment was limited to single-agent alkylator therapy. Within the last two decades, we have seen remarkable progress in...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039008/ https://www.ncbi.nlm.nih.gov/pubmed/21339937 http://dx.doi.org/10.2147/TCRM.S5855 |